Immunology and Infectious Disease (Molecular and Cellular Biology of Critical Care Medicine, 3)

個数:
  • ポイントキャンペーン

Immunology and Infectious Disease (Molecular and Cellular Biology of Critical Care Medicine, 3)

  • ウェブストア価格 ¥21,190(本体¥19,264)
  • Kluwer Academic Pub(2003/01発売)
  • 外貨定価 US$ 109.99
  • ゴールデンウィーク ポイント2倍キャンペーン対象商品(5/6まで)
  • ポイント 384pt
  • 提携先の海外書籍取次会社に在庫がございます。通常3週間で発送いたします。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合が若干ございます。
    2. 複数冊ご注文の場合、分割発送となる場合がございます。
    3. 美品のご指定は承りかねます。
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Hardcover:ハードカバー版/ページ数 276 p.
  • 言語 ENG
  • 商品コード 9781402073076
  • DDC分類 616.90479

基本説明

This unique volume provides a mechanistic look at key aspects of the inflammatory response seen in critical illness.

Full Description

Individualized dosing regimens specific to the patient, infection, bacteria, and antibiotic can optimize outcome. Integration of pharmacokinetic and pharmacodynamic data, called dual individualization, can be accomplished through the use of AUIe. AUIC dosing has been shown to predict bacteriological outcomes, hasten clinical outcomes, reduce the emergence of resistance, and be cost-effective. MPC dosing has been shown to predict the emergence of resistant submutants. AUIC and MPC information can provide guidance as to when low doses can be used, and when higher concentrations are required. This strategy can ensure efficacy, minimize toxicity, reduce the opportunity for resistance to occur, and save money. REFERENCES I. Paladino JA. Streamlining antibiotic therapy: clinical application of pharmacokinetic and pharmacodynamic principles. J Osteopath Med 1991; 5: 16-25. 2. Liss RH, Batchelor FR. Economic evaluations of antibiotic use and resistance - a perspective: report of task force 6. Rev Infect Dis 1987; 9 (suppI3): S297-312. 3. Holmberg SO, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis 1987; 9: 1065-78. 4. Sanders cc.
Mechanisms responsible for cross-resistance and dichotomous resistance among the quinolones. Clin Infect Dis 2001; 32(Suppl I ):S 1-8. 5. Ballow CH, Schentag 11. Trends in antibiotic utilization and bacterial resistance: report of the NNRSG. Diagn Microbiol Infect Dis. 1992; 15(suppl):37S-42S. 6. Rice LB, Eckstein EC, DeVente J, Shlaes OM. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996; 23: 118-24.

Contents

1. Host Microbicidal Actions of the Innate Immune Response.- 2. Activation of the Innate Immune Response in Critical Illness.- 3. Down-Regulation of the Immune Response.- 4. Mechanisms of Pharmacologic Immune Suppression.- 5. Modulation of the Immune Response in Critical Illness/Injury.- 6. Immune Monitoring and Strategies for Immune Modulation.- 7. Central Venous Catheter Related Infections: The Role of Antimicrobial Catheters.- 8. Discrimination of True Lower Respiratory Tract Infection in the Mechanically Ventilated Patient.- 9. Detection of Urinary Tract Infection in the Catheterized ICU Patient.- 10. Antimicrobial Choices and Dosing Strategies to Maximize Efficacy and Minimize the Development of Bacterial Resistance.